Vivos 2025 Q3 Earnings Revenue Surges 75.7% but Net Loss Widens 106.4%

Vivos Therapeutics (VVOS) reported Q3 2025 results marked by a 78% sequential revenue surge to $6.8 million, exceeding expectations, but net losses widened to $5.4 million, a 106.4% increase from 2024. The company reiterated guidance for cash flow breakeven in 2026 amid strategic expansion of Sleep and Airway Medicine Centers (SAMCs).

Revenue

Vivos’ total revenue rose 75.7% to $6.78 million in Q3 2025, driven by the acquisition of The Sleep Center of Nevada (SCN) and expansion of SAMCs. Service revenue dominated, with sleep testing services ($2.56 million) and treatment centers ($1.32 million) leading growth. Product revenue, including appliances ($1.41 million) and guides ($790,000), also contributed. Notable segments included VIP enrollments ($82,000) and billing intelligence services ($184,000).

Earnings/Net Income

The company’s net loss widened to $5.4 million in Q3 2025, a 106.4% increase from $2.62 million in 2024. Earnings per share (EPS) fell to -$0.49, a 22.5% wider loss compared to -$0.40 in 2024. The EPS reflects deteriorating profitability despite revenue growth, underscoring ongoing operational challenges.

Post-Earnings Price Action Review

The strategy of buying Vivos shares on the date of its Q3 2025 earnings announcement and holding for 30 days historically yielded a 17.5% cumulative gain, albeit with an 11.8% maximum drawdown. However, post-earnings trading saw a 2.07% intraday drop, a 6.35% weekly decline, and a 17.19% month-to-date slump, reflecting investor caution amid widening losses.

CEO Commentary

CEO R. Huntsman highlighted Q3 2025 as a “watershed quarter,” crediting the SCN acquisition for $2.7 million in service revenue and $200,000 in product revenue. Challenges included upfront expansion costs and provider credentialing delays, but he expressed confidence in scaling operations, with demand exceeding 40% of capacity. Strategic priorities include expanding SAMCs, credentialing providers for 2026, and replicating the model via affiliations.

Guidance

Management anticipates a 3–6-month ramp for new providers to reach optimized revenue levels post-credentialing, with SAMCs targeting 50–60% contribution margins at scale. Revenue growth is expected to outpace expenses in 2026 as teams expand, with cash flow breakeven as a near-term goal.

Additional News

1. M&A Activity: Vivos completed the $7.5 million acquisition of The Sleep Center of Nevada (SCN) in June 2025, marking a strategic pivot to direct patient care.

2. Executive Appointments: Michael E. Bruhn joined as Executive Vice President of Business Operations Integration, and Dr. Terry Jones became Senior Vice President of Human Resources in July 2025.

3. Product Approval: The VidaSleep™ oral appliance received Medicare approval in July 2025, expanding access to 60 million beneficiaries for treating mild to moderate OSA.